LZLichun Zhao

Lichun Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lichun Zhao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Madecassoside Part I: From Biosynthesis to Druggability

    by Yuping Li, Mengdan Xu, Yuting Yang, Shanshan Liang, Yucui Lu, Xianmei Lin, Lichun Zhao

    Background: Madecassoside (MA) is the core bioactive pentacyclic triterpenoid saponin and a key quality control marker of Centella asiatica (L.) Urb. Its material basis and druggability profiles are fundamental prerequisites for pharmacological research and clinical translation. Although several reviews have covered selected aspects of MA chemistry and pharmacology, no systematic review has comprehensively covered the full chain from chemical structure to in vivo disposition exclusively for MA monomer. Objective: As the first part of a two-part series, this review aims to systematically integrate evidence on the chemical basis, biosynthesis, green preparation, and pharmacokinetic characteristics of MA and clarify the core druggability bottlenecks of this compound. Methods: The literature search was conducted in PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) up to 31 August 2026. Studies focusing on the chemistry, biosynthesis, extraction/purification, and pharmacokinetics of MA were included and critically analyzed. Evidence was stratified into four predefined levels: Level A (clinical trials), Level B (in vivo animal studies), Level C (in vitro cell/molecular studies), Level D (computational prediction). The limitation of Chinese literature to Peking University core journals is acknowledged as a potential source of publication bias. Results: Current evidence supports that the C-6 β-hydroxyl group on the ursane-type aglycone skeleton and the intact linear trisaccharide chain at the C-28 position are the major structural correlates of MA’s biological activity (working hypothesis based on natural analog comparisons). The backbone cyclization and glycosylation steps in the MA biosynthetic pathway have been largely characterized, but the specific enzymes responsible for C-2 α- and C-6 β-hydroxylation remain to be fully identified. Green extraction technologies such as ultrasound-assisted extraction, microwave-assisted extraction, and deep eutectic solvent extraction have been well optimized, and multiple purification strategies can yield high-purity monomers. In rats, the oral absolute bioavailability of the pure MA prototype is less than 1%, with extensive intestinal metabolism and enterohepatic circulation, representing the core druggability bottleneck. Human pharmacokinetic data remain very limited, and rat values cannot be directly extrapolated to humans. Conclusions: This review establishes a full-chain material basis framework for madecassoside spanning from molecular structure to in vivo disposition, systematically integrating evidence on structural activity determinants, biosynthetic pathways, green extraction and purification technologies, and pharmacokinetic profiles. Extremely low oral bioavailability and extensive in vivo metabolic transformation are confirmed as the core druggability bottlenecks. These findings lay the essential foundation for elucidating pharmacological mechanisms, optimizing delivery systems, and advancing clinical translation in the second part of this series. To our knowledge, this is the first two-part systematic review focused exclusively on the MA monomer that covers the full translational spectrum from chemical fundamentals and druggability profiles to pharmacological mechanisms and clinical translation.

  • Top Cited Papers
    Open Access

    The Relationship Between Trace Elements and Depression

    by Yuanjian Zhong, Yuxiang Nie, Yuanhui Mao, Yinting Liu, Tong Zou, Xiayun Liao, Lichun Zhao

    Trace elements are widely involved in fundamental physiological processes, including enzymatic reactions, neurotransmitter metabolism, and redox homeostasis, and their balanced regulation plays an important role in maintaining normal brain development and neurological function. Depression is a complex psychiatric disorder characterized primarily by mood disturbances, with its onset and progression arising from long-term interactions among genetic susceptibility, neurobiological alterations, and environmental factors. A substantial body of epidemiological and clinical evidence indicates that dysregulation of trace elements—such as zinc, selenium, iron, and magnesium—is closely associated with the risk of depression and the severity of depressive symptoms. Mechanistic studies further demonstrate that trace elements influence depression-related pathophysiology through multi-target and multi-pathway mechanisms, including modulation of monoaminergic neurotransmission, neuroinflammation, oxidative stress, mitochondrial energy metabolism, and hypothalamic–pituitary–adrenal axis function. Network pharmacology analyses have additionally identified systemic hub targets, such as albumin (ALB), insulin (INS), and TP53, as well as key pathways including calcium signaling, neuroactive ligand–receptor interactions, and the HIF-1 signaling pathway. These findings suggest that trace elements may regulate depression-related pathological processes through coordinated network-level effects. Collectively, these integrative insights provide a theoretical basis for the application of trace elements in depression risk assessment, the development of precision intervention strategies, and future mechanistic investigations.